



Syndicated Thought Leader Insight

Thought Leader Insight & Analysis Report **Anticoagulants Q1 2010**

Therapeutic Class:	Cardiovascular
Focus Area:	Anticoagulants
Specialty/Location:	Cardiology, Orthopedic Surgery/N. America, Europe
Number of Interviews:	7
Number of Pages:	126
Publication Date:	January 2010
Principal Authors:	Tricia L. Hanlon Kim Grant Jeffrey D. Berk, Ph.D., MBA
Product Code:	MCVQ110-8
Pricing:	\$7,500
Order Info:	www.medpredict.com or call (513) 271-1924

Summary: This report is based on interviews with seven Thought Leaders who have a stake in anticoagulation therapy. The discussions took place in January 2010. This Panel continues where our last report left off, exploring the revolutionary use of antithrombotics and antiplatelets for use in the prevention of ischemic events during/after surgery, acute coronary syndrome, secondary prevention venous thromboembolism and secondary prevention for atrial fibrillation.

Together, the insights from these interviews can be thought of as a “war-game”, laying out the competitive strengths and weaknesses of marketed products and experimental therapeutics with high likelihood of being commercialized. Panelists differentiate each drug based on clinical trial design, anticoagulant efficacy, increased bleeding risk, convenience, associated therapeutic limitations and costs.

Drugs/devices discussed in this report include:

Company	Generic	Brand
AstraZeneca	AZD-0837 ticagrelor (AZD-6140) ximelagatran	Brilinta Exanta (withdrawn)
Atritech	left atrial appendage device	Watchman
Bayer-Schering / J&J	rivaroxaban	Xarelto
Boehringer Ingelheim	dabigatran	Pradaxa
Bristol-Myers Squibb	warfarin	Coumadin
BMS / Pfizer	apixaban	
BMS / S-A	clopidogrel	Plavix
Daiichi Sankyo	edoxaban (DU-176b)	
Daiichi Sankyo / Lilly	prasugrel	Effient
Portola / Merck Portola / Novartis	betrixaban (PRT054021) elinogrel (PRT060128)	
Sanofi-Aventis	enoxaparin idrabioparinix (SSR-126517E)	Lovenox
Schering-Plough / Merck	SCH530348 (Thrombin Receptor Antagonist)	
The Medicines Company	cangrelor bivalirudin	Angiomax

Table of Contents

Executive Summary3

Report Highlights..... 4

Key Findings13

Antithrombotics 13

Lovenox; enoxaparin (Sanofi-Aventis)..... 13

Pradaxa (dabigatran; Boehringer-Ingelheim) 18

Xarelto (rivaroxaban; Bayer-Schering / J&J) 26

apixaban (Bristol-Myers Squibb / Pfizer) 30

betrixaban (Portola / Merck) 31

edoxaban (Daiichi Sankyo) 32

idrabioparinix (SSR126517E; Sanofi-Aventis)..... 32

AZD0837 (AstraZeneca) 33

Angiomax; bivalirudin (The Medicines Company) 33

Antiplatelets..... 35

Plavix (clopidogrel; Bristol-Myers Squibb / Sanofi-Aventis) 35

Effient (prasugrel; Daiichi Sankyo / Lilly)	36
Brilinta (ticagrelor; AstraZeneca)	47
cangrelor (The Medicines Company)	55
elinogrel (PRT-128; Portola / Novartis).....	56
SCH530348 (Thrombin Receptor Antagonist; Schering-Plough / Merck).....	59
Devices for SPAF.....	66
Watchman	66
Thought-Leader Discussions.....	69
Interview CV02380.....	69
Interview CV02381	76
Interview CV02382.....	84
Interview CV02383.....	92
Interview CV02384.....	103
Interview CV02386.....	112
Interview CV02388.....	120